You are just seeing the tip of the iceberg, the Axdx capability for ID and AST is unique in that the ID is done using phenotypic method, quick broth growth followed by microscopy to get an ID answer in two hours AND then using the same specimen conducting the AST analysis for drug resistance. The part nobody is getting, is that every other molecular ID company ; Cepheid, BD, BioMerieux all KILL the bug specimen in the process of ID ing it. Ergo, there is no exact same bug left to do the Susceptibility testing. The Axdx cartridge is pre loaded on the front end of the test filling both chambers for ID and AST with same blood specimen or BAL fluid for accurate results. The company can do direct from blood, it just isn't going to market with that initial product. Show the FDA what they understand first and then extend the approval in subsequent steps. The prize is the ultimate bending of the curve of lowering the 100,000 preventable deaths from HAI (hospital acquired infections) and the failure of empiric therapy to prevent mortality from pneumonia as a result of 2-4 day delay in getting actionable culture results back from the lab. This is going to become the new standard of care and the IP will keep it all in Axdx's portfolio. Stay patient and ignore the claims of imitators. They have "small hands"!!